The Technical Analyst
CytomX Therapeutics Inc [CTMX]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
CytomX Therapeutics Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
-5.38% $1.760
America/New_York / 17 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 119.19 mill |
| EPS: | -0.0100 |
| P/E: | -176.00 |
| Earnings Date: | May 07, 2024 |
| SharesOutstanding: | 67.72 mill |
| Avg Daily Volume: | 0.922 mill |
| RATING 2024-04-17 |
|---|
| B- |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Sell | |
| Return On Equity: | Sell | |
| Return On Asset: | Buy | |
| DE: | Strong Sell | |
| P/E: | Strong Buy | |
| Price To Book: | Strong Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -176.00 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -29.94x |
| Company: PE -176.00 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 1.581 - 1.939 ( +/- 10.17%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-03-26 | Mccarthy Sean A. | Buy | 109 768 | Common Stock |
| 2024-03-26 | Mccarthy Sean A. | Sell | 109 768 | Stock Option (Right to Buy) |
| 2024-03-20 | Su Zhen | Buy | 76 000 | Stock Option (Right to Buy) |
| 2024-03-20 | Su Zhen | Buy | 0 | |
| 2024-03-19 | Rowland Lloyd A | Sell | 5 268 | Common Stock |
| INSIDER POWER |
|---|
| 64.81 |
| Last 98 transactions |
| Buy: 4 891 928 | Sell: 1 103 909 |
Forecast:
16:00 - $1.760
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $1.760
Forecast 2: 16:00 - $1.760
Forecast 3: 16:00 - $1.760
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $1.760 (-5.38% ) |
| Volume | 0.585 mill |
| Avg. Vol. | 0.922 mill |
| % of Avg. Vol | 63.45 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For CTMX
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
CTMX
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical trials for the treatment of breast cancer; CX-2029 that is in Phase II clinical trials for the treatment of squamous non-small cell lung cancer, head and neck squamous cell carcinoma, esophageal and gastro-esophageal junction cancers, and diffuse large B-cell lymphoma; BMS-986249, a CTLA-4 Probody therapeutic drug, which is in Phase I/II clinical trials for the treatment of metastatic melanoma; and BMS-986288, an anti-CTLA-4 Probody drug, which is in Phase I clinical trials for the treatment of solid tumors. It also develops CX-2043, a conditionally activated ADC targeting the epithelial cell adhesion molecule, as well as CX-904, a conditionally activated epidermal growth factor receptor for the treatment of solid tumor. The company has strategic collaborations with AbbVie Ireland Unlimited Company, Amgen, Inc., Bristol-Myers Squibb Company, ImmunoGen, Inc., Pfizer Inc., and Astellas Pharma Inc. to develop Probody therapeutics. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.
Latest Press Releases
2024-04-08 08:00:00 - Press Release
Cytomx Therapeutics Announces First Patient Dosed With Cx-2051, A Conditionally Activated Epcam-directed Adc, In A Phase 1 Study In Patients With Advanced Solid Tumors
South san francisco, calif., april 08, 2024 (globe newswire) -- cytomx therapeutics, inc. (nasdaq: ctmx), a leader in the field of conditionally activated, localized biologics, today announced the first patient has been dosed in a phase 1 dose escalation study (nct06265688) of cx-2051 in patients with advanced solid tumors. cx-2051 is a masked probody® antibody drug conjugate (adc) directed toward epithelial cell adhesion molecule (epcam), a cell-surface target that is highly expressed across many cancer types including colorectal, gastric, endometrial, and ovarian cancers. the cytotoxic payload utilized in cx-2051 is a derivative of camptothecin, a topoisomerase-1 inhibitor, a class of drug that has shown potent clinical anti-cancer activity and demonstrated significant clinical benefit as an approved adc in multiple cancers...
2024-04-03 08:00:00 - Press Release
Cytomx Therapeutics Announces Nomination Of Second Clinical Candidate In Broad Probody® T-cell Engaging Bispecific (tcb) Collaboration With Astellas
- achievement of latest clinical candidate triggers additional $5 million milestone payment to cytomx and is the third milestone achieved in the collaboration to date -
2024-03-21 08:00:00 - Press Release
Cytomx Therapeutics Appoints Dr. Zhen Su To Board Of Directors
South san francisco, calif., march 21, 2024 (globe newswire) -- cytomx therapeutics, inc. (nasdaq: ctmx), a leader in the field of conditionally activated, localized biologics, today announced the appointment of zhen su, m.d., m.b.a., an experienced physician executive and leader in the development of oncology therapeutics, to the company's board of directors.
2024-03-18 08:00:00 - Press Release
Cytomx Therapeutics Announces Milestone Achievement In Probody® t-cell Engaging Bispecific (tcb) Collaboration With Astellas
- initiation of glp toxicology study for the first clinical candidate in the collaboration triggers a $5 million milestone payment to cytomx -
2024-03-11 16:10:00 - Press Release
Cytomx Therapeutics Reports 2023 Financial Results And Provides Business Update
- cx-904 (egfrxcd3 t-cell engager) initial phase 1a dose escalation data in solid tumors anticipated in the 2nd half of 2024 -
Latest News
2024-03-12 09:12:55 - InvestorPlace
Why Is CytomX Therapeutics (CTMX) Stock Down 18% Today?
CytomX Therapeutics (NASDAQ: CTMX ) stock is falling hard on Tuesday after the clinical-stage, oncology-focused biopharmaceutical company released its latest earnings report. The CytomX Therapeutics earnings report notes that the company spent most of 2023 cutting costs to continue operations.
2024-03-11 18:39:06 - Seeking Alpha
CytomX Therapeutics, Inc. (CTMX) Q4 2023 Earnings Call Transcript
CytomX Therapeutics, Inc. (NASDAQ:CTMX ) Q4 2023 Results Conference Call March 11, 2024 5:00 PM ET Company Participants Chris Ogden - Senior Vice President, Finance and Accounting Sean McCarthy - Chief Executive Officer and Chairman Conference Call Participants Joe Catanzaro - Piper Sandler Malcolm Kuno - JPMorgan Operator Good day, and thank you for standing by. Welcome to the CytomX Therapeutics Fourth Quarter 2023 Financial Results Conference Call.
2024-03-11 18:21:05 - Zacks Investment Research
CytomX Therapeutics (CTMX) Lags Q4 Earnings Estimates
CytomX Therapeutics (CTMX) came out with quarterly earnings of $0.01 per share, missing the Zacks Consensus Estimate of $0.02 per share. This compares to loss of $0.42 per share a year ago.
2024-03-04 08:00:00 - GlobeNewsWire
CytomX Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on March 11, 2024
SOUTH SAN FRANCISCO, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today announced that it will report full year 2023 financial results on Monday, March 11, 2024, after the close of U.S. markets. Following the announcement, the Company will host a conference call and webcast at 5:00 p.m. ET / 2:00 p.m. PT.
2024-02-27 12:56:04 - Zacks Investment Research
CytomX (CTMX) to Report Q4 Earnings: Here's What to Expect
Investor focus is likely to be on CytomX Therapeutics' (CTMX) updates on key cancer immunotherapeutic candidates, CX-904 and BMS-986288, on the fourth-quarter 2023 earnings call.
2024-01-12 08:00:00 - GlobeNewsWire
CytomX Therapeutics to Present at the B. Riley Securities Virtual Annual Oncology Conference
SOUTH SAN FRANCISCO, Calif., Jan. 12, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today announced that Sean McCarthy, D.Phil., president, chief executive officer, and chairman, will participate in a fireside chat at the B. Riley Securities Virtual Annual Oncology Investor Conference on Thursday, January 18, 2024 at 1:00 p.m. ET.
2023-12-21 08:00:00 - GlobeNewsWire
CytomX Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Dec. 21, 2023 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today announced that Sean McCarthy, D.Phil., president, chief executive officer, and chairman, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024 at 5:15 p.m. PT.
2023-11-13 13:32:23 - Zacks Investment Research
CytomX Therapeutics (CTMX) Upgraded to Strong Buy: What Does It Mean for the Stock?
CytomX Therapeutics (CTMX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
2023-11-08 02:32:12 - Seeking Alpha
CytomX Therapeutics, Inc. (CTMX) Q3 2023 Earnings Call Transcript
CytomX Therapeutics, Inc. (NASDAQ:CTMX ) Q3 2023 Earnings Conference Call November 7, 2023 5:00 PM ET Company Participants Chris Ogden - Senior Vice President, Finance and Accounting Sean McCarthy - Chief Executive Officer and Chairman Conference Call Participants Roger Song - Jefferies. Jade Montgomery - H.C.
2023-10-31 08:00:00 - GlobeNewsWire
CytomX Therapeutics to Report Third Quarter 2023 Financial Results on November 7, 2023
SOUTH SAN FRANCISCO, Calif., Oct. 31, 2023 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today announced that it will report third quarter financial results on Tuesday, November 7, 2023, after the close of U.S. markets. Following the announcement, the Company will host a conference call and webcast at 5:00 p.m. ET / 2:00 p.m. PT.